Boston Scientific (NYSE:BSX) this week unveiled full results from the PREVAIL clinical trial of the Watchman anti-stroke implant, largely agreeing with earlier reports that the device missed a co-primary endpoint for efficacy.
I just returned from the American College of Cardiology and wanted to write down a few of my 50,000-foot impressions from the meeting for, as the song goes, the times, they are a-changin’.
UPDATED March 31, 2014, with comment from Medtronic
Welcome to the latest edition of the MassDevice.com’s D+Vice Talk, our new webcast, in which we review medical device stories from the last week.
In this episode we start with updates from Capitol Hill, review highlights from the American College of Cardiology conference, consider the mixed FDA reports for Abbott’s MitraClip heart implant and debate Dr. Robert Hauser’s controversial proposal to overhaul the FDA.
Find all of today’s referenced stories here: